Trials / Recruiting
RecruitingNCT05753826
Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.
A Single-arm, Exploratory Study of Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (estimated)
- Sponsor
- Fujian Cancer Hospital · Other Government
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, exploratory study. People with recurrent platinum-resistant ovarian cancer who have not received any previous systemic antitumor therapy for ovarian cancer were selected to evaluate the efficacy and safety of adebrelimab combined with fuzuloparib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adebrelimab | 20mg/kg，D1，q3W |
| DRUG | Fuzuloparib | 100 mg bid |
Timeline
- Start date
- 2023-08-01
- Primary completion
- 2025-12-31
- Completion
- 2027-12-31
- First posted
- 2023-03-03
- Last updated
- 2024-02-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05753826. Inclusion in this directory is not an endorsement.